University of Pisa-ko ikertzaileekin lankidetzan egindako argitalpenak (12)

2024

  1. OMERACT systemic lupus erythematosus domain survey

    Seminars in Arthritis and Rheumatism, Vol. 68

2023

  1. Evaluating the Construct of Damage in Systemic Lupus Erythematosus

    Arthritis Care and Research, Vol. 75, Núm. 5, pp. 998-1006

  2. Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases

    The Lancet Rheumatology

2022

  1. Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic

    Lupus Science and Medicine, Vol. 9, Núm. 1

2021

  1. Impact of glucocorticoids on the incidence of lupus-related major organ damage: A systematic literature review and meta-regression analysis of longitudinal observational studies

    Lupus Science and Medicine, Vol. 8, Núm. 1

  2. What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts

    Lupus Science and Medicine, Vol. 8, Núm. 1

2020

  1. Comparative study between two european inception cohorts of patients with early systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 38, Núm. 5, pp. 925-932

  2. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 10, pp. 1333-1339

2019

  1. EULAR recommendations for the management of antiphospholipid syndrome in adults

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 10, pp. 1296-1304

  2. Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 5, pp. 634-640

2018

  1. Tacrolimus in non-Asian patients with SLE: A real-life experience from three European centres

    Lupus Science and Medicine, Vol. 5, Núm. 1

2013

  1. Off-Label Use Of Rituximab For Systemic Lupus Erythematosus in Europe: Limited Use Mostly In Refractory Patients

    ARTHRITIS AND RHEUMATISM